Top Markets
#1 Nesa Nesa +816.77%
#2 Cortex Cortex +68.49%
#3 Merlin's Seal BTC Merlin's Seal BTC +45.50%
#4 QuantixAI QuantixAI +23.90%
#5 EXOD EXOD +22.78%
#6 BSquared Network BSquared Network +19.70%
#7 Pons Pons +18.22%
#8 Instadapp Instadapp +16.92%
#9 Magma Finance Magma Finance +12.52%
#10 OpenEden OpenEden +11.84%
Coin of the day
Nesa Nesa
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Shenzhen Salubris Pharmaceuticals Co., Ltd. Shenzhen Salubris Pharmaceuticals Co., Ltd.

Shenzhen Salubris Pharmaceuticals Co., Ltd.

002294
Classement en actions #3529
Established in 1998 and headquartered in Shenzhen, China, Shenzhen Salubris... Established in 1998 and headquartered in Shenzhen, China, Shenzhen Salubris Pharmaceuticals Co., Ltd. operates across the entire pharmaceutical value chain, from research and development to manufacturing and sales. The company primarily focuses on critical therapeutic areas within China, including cardiovascular, anti-diabetic, anti-cancer, and orthopedic medicine. Its diverse product portfolio features a variety of cardiovascular and cerebrovascular medications, such as allisartan isoproxil and clopidogrel bisulfate tablets, alongside injectable options like bivalirudin. A significant offering is the recombinant SeV-hFGF2/dF Injection, specifically developed for the treatment of diabetic foot disease. Salubris also manufactures anti-tumor and orthopedic drugs. Furthermore, its anti-infective range encompasses numerous injectable antibiotics, including ceftazidime and ceftriaxone sodium, as well as oral preparations such as azithromycin dispersible and levetiracetam tablets. The firm also innovates in biotechnological drugs, developing recombinant proteins and monoclonal antibodies. Complementing its domestic operations, Shenzhen Salubris Pharmaceuticals engages in the import, in-licensing, and out-licensing of medicines, particularly for European markets.
Prix de l'action
$4.64
Capitalisation boursière
$5.18B
Changement (1 jour)
0.41%
Changement (1 an)
-37.42%
Pays
CN
Échange Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294)

Catégorie

Healthcare
Bénéfices pour Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294)
Bénéfices en 2026 TTM : 0
Selon les derniers rapports financiers de Shenzhen Salubris Pharmaceuticals Co., Ltd., les bénéfices actuels de l'entreprise sont de 0. En 2026, l'entreprise a réalisé un bénéfice de 0, égal à celui de 2026 qui était de 0. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour Shenzhen Salubris Pharmaceuticals Co., Ltd. de 2026 à 2026
Bénéfices à la fin de chaque année
Année Bénéfices Changez
Pas assez de données pour les dates fournies.
Bénéfices des entreprises similaires ou concurrentes
Entreprise Bénéfices Différence de bénéfices Pays
Intuitive Surgical, Inc. Intuitive Surgical, Inc.
Intuitive Surgical, Inc.
ISRG.US
$3.81B -
US
EssilorLuxottica S.A. EssilorLuxottica S.A.
EssilorLuxottica S.A.
EL.PA
$4.11B -
FR
HOYA Corporation HOYA Corporation
HOYA Corporation
7741.T
- -
JP
Becton, Dickinson and Company Becton, Dickinson and Company
Becton, Dickinson and Company
BDX.US
$1.59B -
US
Alcon Inc. Alcon Inc.
Alcon Inc.
ALC.SW
- -
CH